Entity

Time filter

Source Type

Ouagadougou, Burkina Faso

Tapsoba T.L.,Service de medicine nucleaire | Diendere G.G.W.,Service de medicine nucleaire | Sanon H.,Service de medicine nucleaire | Ouattara T.F.,Service de medicine nucleaire | And 4 more authors.
Medecine Nucleaire | Year: 2013

Bone scintigraphy 99mTc-MDP is a test carried out at the university hospital CHUYO since January 2012. After a few months of operation, our aim is to study the contribution of bone scintigraphy in the staging of cancer at the university hospital Yalgado Ouedraogo. This is a retrospective descriptive study conducted from January 2012 to March 2013. Seventy (70) patients were included in the study, all with a known or unknown primary tumor, and who have received a bone scan in search of bone metastases. Bone scintigraphy was performed using 99mTc-MDP at the late phase, an average of 3hours after injection. Of the seventy (70) patients in the study, fifty-six (56) patients or 80% of cases had a known primary tumor. Of these patients, 23 (41%) had prostate cancer and 22 or 39.3% of cases had breast cancer. Forty-four (44) patients or 78.6% of cases received a bone scan as part of the monitoring of cancer. Bone scintigraphy has revealed some suspect hyperfixations of bone metastases in 45.8% of patients. The spine, pelvis and ribs were the sites most frequently affected by metastases. Prostate and breast cancers were the most frequent. The diagnostic value of bone scintigraphy is mainly due to its high sensitivity, which enables an early diagnosis. As for further exploration, the results must be considered in the clinical context. © 2013. Source

Discover hidden collaborations